Shu Feng

No. 9 Beijing Road
Guiyang, 550004, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

AKR1C3 promotes aerobic glycolysis in hepatic stellate cells via the AKT/mTOR pathway to induce liver fibrosis.

AKR1C3 promotes aerobic glycolysis in hepatic stellate cells via the AKT/mTOR pathway to induce liver fibrosis.

Journal: Cellular signalling
Published: October 05, 2025

Role of NLRP3 in the metabolism of bile acids and gut microbiota in CCl4-induced liver fibrosis.

Role of NLRP3 in the metabolism of bile acids and gut microbiota in CCl4-induced liver fibrosis.

Journal: Microbiology spectrum
Published: July 21, 2025

Glycochenodeoxycholic acid induces the release of IL-1beta from L02 cells via the NLRP3/caspase-1/GSDMD pathway to activate LX2 cells.

Glycochenodeoxycholic acid induces the release of IL-1beta from L02 cells via the NLRP3/caspase-1/GSDMD pathway to activate LX2 cells.

Journal: Journal of inflammation research
Published: April 02, 2025

Correction: Bile acids induce liver fibrosis through the NLRP3 inflammasome pathway and the mechanism of FXR inhibition of NLRP3 activation.

Correction: Bile acids induce liver fibrosis through the NLRP3 inflammasome pathway and the mechanism of FXR inhibition of NLRP3 activation.

Journal: Hepatology international
Published: March 27, 2025

Activation of gut FXR improves the metabolism of bile acids, intestinal barrier, and microbiota under cholestatic condition caused by GCDCA in mice.

Activation of gut FXR improves the metabolism of bile acids, intestinal barrier, and microbiota under cholestatic condition caused by GCDCA in mice.

Journal: Microbiology spectrum
Published: February 21, 2025

Catalpol ameliorates liver fibrosis via inhibiting aerobic glycolysis by EphA2/FAK/Src signaling pathway.

Catalpol ameliorates liver fibrosis via inhibiting aerobic glycolysis by EphA2/FAK/Src signaling pathway.

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology
Published: July 03, 2024

Role of gut/liver metabolites and gut microbiota in liver fibrosis caused by cholestasis.

Role of gut/liver metabolites and gut microbiota in liver fibrosis caused by cholestasis.

Journal: International immunopharmacology
Published: June 12, 2024

Network pharmacology and transcriptomic profiling elucidate the therapeutic effects of Ranunculus ternatus Thunb on liver fibrosis via MK3-NF-κB inhibition.

Network pharmacology and transcriptomic profiling elucidate the therapeutic effects of Ranunculus ternatus Thunb on liver fibrosis via MK3-NF-κB inhibition.

Journal: Aging
Published: October 24, 2023

Bile acids induce liver fibrosis through the NLRP3 inflammasome pathway and the mechanism of FXR inhibition of NLRP3 activation.

Bile acids induce liver fibrosis through the NLRP3 inflammasome pathway and the mechanism of FXR inhibition of NLRP3 activation.

Journal: Hepatology international
Published: March 28, 2023

Alpha-linolenic acid inhibits hepatocellular carcinoma cell growth through Farnesoid X receptor/β-catenin signaling pathway.

Alpha-linolenic acid inhibits hepatocellular carcinoma cell growth through Farnesoid X receptor/β-catenin signaling pathway.

Journal: Nutrition & metabolism
Published: March 23, 2022

Acyl-CoA Thioesterase 7 is Transcriptionally Activated by Krüppel-Like Factor 13 and Promotes the Progression of Hepatocellular Carcinoma.

Acyl-CoA Thioesterase 7 is Transcriptionally Activated by Krüppel-Like Factor 13 and Promotes the Progression of Hepatocellular Carcinoma.

Journal: Journal of hepatocellular carcinoma
Published: September 09, 2021

Focal adhesion kinase-related non-kinase ameliorates liver fibrosis by inhibiting aerobic glycolysis via the FAK/Ras/c-myc/ENO1 pathway.

Focal adhesion kinase-related non-kinase ameliorates liver fibrosis by inhibiting aerobic glycolysis via the FAK/Ras/c-myc/ENO1 pathway.

Journal: World journal of gastroenterology
Published: July 14, 2021
Showing 1-12 of 12

Last Updated: 09/26/2026